Efalizumab
- Generic Name
- Efalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 214745-43-4
- Unique Ingredient Identifier
- XX2MN88N5D
- Background
Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It was later withdrawn in 2009 due to a poten...
- Indication
For the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
- Associated Conditions
- Moderate to Severe Chronic Plaque Psoriasis
- Associated Therapies
- -
Safety and Efficacy of a Monoclonal Antibody for Treatment of Rheumatoid Arthritis.
- Conditions
- First Posted Date
- 2002-04-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- XOMA (US) LLC
- Registration Number
- NCT00034203
- Locations
- 🇺🇸
Wallace Rheumatic Study Center, Los Angeles, California, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸The San Diego Arthritis and Osteoporosis Medical Clinic, San Diego, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.